Symbio Research
Dr. Andreas Pfaff has extensive work experience in scientific and regulatory affairs, clinical operations, and project management. Dr. Andreas currently holds the position of Head of Scientific and Regulatory Affairs at Symbio Research since November 2020. Previously, they served as the Director of Clinical Operations and Regulatory Affairs at the same company from January 2019 to November 2020. Before joining Symbio Research, Dr. Pfaff worked at Proinnovera GmbH, where they held various roles, including Regulatory Affairs Manager from June 2015 to December 2018, Project Manager from June 2010 to May 2015, and CRA/Lead CRA from November 2008 to May 2010. Prior to their time at Proinnovera GmbH, they worked as a CRA at IST GmbH from July 2005 to October 2008.
Dr. Andreas Pfaff obtained their degree, Dr. phil. nat., in Biology/Biological Sciences from the Goethe University Frankfurt in 2004.
This person is not in any offices
Symbio Research
Headquartered in Port Jefferson, NY, Symbio is a client-focused global full service Clinical Research Organization (CRO). We manage all CRO core services in house and have our offices in the USA and Europe. We deliver excellent service and provide experienced qualified personnel to strategically manage all aspects of your clinical trials. Symbio offers expertise in Proof-of-Concept, medical device and Phase I – Phase IV clinical studies and has completed over 115 clinical studies to date, both in the USA and in other territories. Developing and maintaining excellent relationships with experienced clinical research sites are vital to the success of any study and every CRO. As a direct result of our site relationships, Symbio trials receive the special attention they deserve. We take great pride in the strong relationships we have established through the years. These relationships have provided us the ability to streamline recruitment, creating shorter enrollment timelines with a lower number of sites. Our expertise starts from the top. Symbio, LLC was founded in 2002 by Richard Panico and Debra Dow. With previous leadership roles in CRO management and product development, Rich and Deb have been able to successfully grow their company by carefully selecting qualified clinical research professionals. In collaboration with senior management, their continued oversight offers clients a personalized experience ensuring study management challenges are anticipated, identified and resolved quickly and efficiently. In 2018 Richard Panico, Debra Dow and Veronika Kunert founded Symbio’s subsidiary in Europe to support our clients with their global clinical trials. The vision from the start has been to create a CRO that consistently delivers outstanding service and quality to sponsors. The common goal is to bring clinical studies to a successful end, on time and on budget.